Stem-cell injections and IVs: verify the product and FDA status
Before a stem-cell injection or IV, match the exact product and use to one path: FDA approval/licensure; a product-specific basis meeting every section 361 criterion; or a legitimate investigation under an IND in effect. A clinic's 361 claim, registration, or screenshot is not FDA agreement or marketing approval.
“Stem cell” is a material description, not proof that a clinic’s product is FDA approved. Before an injection or IV, identify the exact cell source, processing, manufacturer, finished product, route, and intended use; then match those facts to one of three bounded paths: an exact FDA approval or biologics license for that product and use; a documented, product-specific basis showing that every criterion for regulation solely under section 361 is met; or a legitimate clinical investigation under an IND that is in effect. A clinic’s section 361 assertion, facility registration, RMAT designation, or ClinicalTrials.gov listing is not FDA agreement or permission to market the treatment as approved.124568
This verification is intentionally product-specific. The current existence of FDA-approved cellular therapies does not validate a different office injection for joint pain, an IV for fatigue, or a procedure marketed for anti-aging.
Start with a product identity, not a therapy nickname
“Your own cells,” “birth tissue,” “umbilical product,” “Wharton’s jelly,” “amniotic,” “adipose-derived,” “bone-marrow concentrate,” and “mesenchymal stem cells” do not identify the same thing. A clinic should be able to complete one traceable sentence:
We obtain [named tissue or cells] from [autologous or donor source], process it by [named method and facility], provide the finished [product name and manufacturer] through [route], for the intended use [condition or claim], under [approval record or protocol for an IND that is in effect].
If the sentence stops at “regenerative,” the consumer cannot verify composition, viable-cell claim, sterility controls, dose, regulatory pathway, or whether the evidence concerns the offered product.
| Claim shown by a clinic | What the record can establish | What it does not establish |
|---|---|---|
| FDA-approved stem-cell therapy | A named product has an FDA approval for a stated indication, population, route, labeling, and manufacturer | That another cell product or an office wellness use is approved |
| 361 HCT/P | The establishment asserts the product meets all criteria for regulation solely under section 361 | That FDA approved the product or agreed with the clinic's classification |
| IND or clinical trial | A specific investigational product may be studied under a defined protocol with eligibility, consent, oversight, and sponsor records | That the product is proven, marketed lawfully outside the study, or appropriate for everyone |
| RMAT designation | An eligible investigational regenerative therapy received an expedited-development designation | Marketing approval or validation of a clinic using a similarly described material |
| FDA registered | An establishment submitted registration information required for its regulated activity | Approval of the product, treatment, facility quality, or medical claim |
Approved cell therapies are narrow, named products
FDA’s current approved cellular and gene therapy list contains specific products for specific indications.1 In December 2024, FDA approved Ryoncil, a bone-marrow-derived mesenchymal stromal cell therapy, for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older.3 That was a landmark approval. It is also an example of why exact language matters: product, source, manufacturing, age, disease, prior-treatment context, route, and labeling are bounded.
Ryoncil’s approval does not create class approval for mesenchymal cells. It does not support an orthopedic injection, cosmetic procedure, anti-aging infusion, recovery drip, autism claim, chronic-pain package, or wellness membership using a different material. Likewise, an approved blood-forming cell product or genetically modified cell therapy cannot lend its status to a clinic merely because both use the word “cell.”
Use the FDA list or Drugs@FDA/Purple Book record to find the exact proprietary name and applicant. Compare the indication and route with the consent form. A statement such as “stem cells are FDA approved” is too broad to be useful and may be materially misleading.
Autologous and minimally processed are not automatic exemptions
Some human cells, tissues, and cellular and tissue-based products can be regulated solely under section 361 of the Public Health Service Act and related rules when all criteria are met. FDA guidance analyzes, among other things, minimal manipulation and homologous use—whether the tissue is used to perform the same basic function in the recipient as in the donor.4 Products that do not meet all criteria may be regulated as drugs, devices, or biological products and require an applicable premarket pathway.
“Same day,” “from your own body,” “surgical procedure,” or “minimally manipulated” is a clinic’s characterization until the actual tissue, processing, use, and regulatory basis are shown. Centrifuging, isolating, expanding, combining, enzymatically processing, or changing the intended function can affect the analysis, but a consumer should not attempt the legal classification from a brochure.
Ask the manufacturer or clinic to identify the precise regulatory provision it relies on and provide any FDA correspondence it claims supports that position. A general registration certificate or screenshot of an establishment database cannot substitute for product-level analysis.
A real trial is a protocol, not a sales label
An investigational product can be studied without marketing approval. FDA explains that an IND generally goes into effect 30 days after FDA receives it unless the agency places the investigation on clinical hold, or earlier if FDA notifies the sponsor that it may proceed.8 A legitimate study has a sponsor, protocol identifier, actual study site, named investigator, eligibility criteria, informed-consent document, institutional review board information, intervention details, costs or payments, monitoring, adverse-event process, and a contact independent of the salesperson.
ClinicalTrials.gov explicitly warns that the U.S. government does not review or approve the safety and science of every study listed on the site.6 A listing can be submitted by a sponsor or investigator; it is a registry record, not an FDA endorsement. Confirm that the clinic address and investigator appear on the current record and that the offered product, route, condition, and enrollment status match.
Charging a participant is not, by itself, proof of fraud or legitimacy. Ask what is routine care, what is research, who pays for complications, and whether the IND sponsor obtained FDA’s prior written authorization to charge for the investigational product.9 That authorization does not decide every routine-care or service charge. Do not accept “your payment funds the study” as the only record.
RMAT is an expedited-development designation, not approval
FDA’s Regenerative Medicine Advanced Therapy program can provide expedited interactions and review tools for qualifying investigational products addressing serious or life-threatening conditions when preliminary clinical evidence indicates the potential to address unmet need.5 RMAT status is meaningful to the product’s sponsor and development program. It is not marketing authorization.
Require the exact product and sponsor named in the designation. A clinic cannot borrow another company’s designation, a related ingredient’s designation, or the general phrase “advanced regenerative medicine.” Even for the designated product, the offered use must be inside a clinical investigation permitted to proceed or later approved labeling as applicable.
The same discipline applies to “patented,” “IRB reviewed,” “GMP facility,” “research use,” and “physician supervised.” Each can describe one record. None proves approval, clinical benefit, or a lawful patient-specific route by itself.
The risk and continuity plan must follow the material
FDA’s May 2026 warning describes complaints involving deaths and serious harm following unapproved human cell and tissue products and explains that FDA has not reviewed such products for quality, safety, purity, or potency when required approval is absent.2 The exact risk profile depends on the product, processing, route, recipient, and setting.
Before any procedure, capture the source eligibility and donor-screening framework when applicable, manufacturing or processing site, lot or unique identifier, sterility and release testing, storage and shipping conditions, dose or cell count and how it was measured, additives, administration supplies, and chain of custody. Ask who is medically responsible during and after treatment, where urgent evaluation occurs, and how the product record reaches that team.
An IV, joint injection, spinal-area procedure, facial injection, or topical application creates different exposure and escalation questions. Do not use a general “regenerative therapy” consent for several routes.
Marketing evidence needs the same exact match
Testimonials, before-and-after images, conference posters, animal research, and studies of other products cannot establish the offered product’s benefit. FTC’s 2025 enforcement against stem-cell marketers concerned unsupported efficacy claims and false or misleading claims that treatments were FDA approved.7 A disclaimer such as “results vary” does not cure a specific disease-treatment or approval representation.
For every cited study, compare source tissue, processing, cell characterization, viability, dose, route, indication, comparator, follow-up, and sponsor with the clinic’s offering. If several of those fields differ, the study is background—not product-specific proof.
PRP, PRF, and exosome products need their own analysis. The PRP-versus-PRF guide covers autologous blood preparations, while the exosome route guide addresses products that are not cells. Neither should be renamed “stem-cell therapy” to simplify a menu.
Verify before payment, then preserve the treatment record
- Freeze the product description. Get the cell or tissue source, donor relationship, processing, manufacturer, product name, lot, route, dose, and proposed indication in writing.
- Match the regulatory path. Find the exact FDA approval and labeling, or verify the study protocol and that its IND is in effect. Treat registration and designations as separate facts.
- Audit the evidence match. Compare the offered material, processing, route, population, condition, and dose with every study used to market it.
- Verify people and place. Check the named Florida clinicians, actual treatment address, responsible investigator when applicable, and emergency receiving plan.
- Price the whole episode. Separate procedure, product, imaging or labs, study-related charges, follow-up, complications, additional sessions, and refunds.
- Keep reporting routes. Preserve identifiers and contacts for the clinic, study sponsor, FDA MedWatch or biologics reporting, Florida licensing review, and urgent clinical care.
The decisive question is: “What exact cell product, route, indication, manufacturer, and lot are you offering, and which matching record applies: FDA approval or licensure for this product and use, a product-specific basis meeting every applicable section 361 criterion, or a clinical investigation under an IND that is in effect?”
Sources
- U.S. Food and Drug Administration. Approved cellular and gene therapy products. Current FDA list showing that marketing approval attaches to named cellular or gene products with specific indications, not to a broad stem-cell category. Accessed .
- U.S. Food and Drug Administration. Patient and consumer warning about unapproved human cell and tissue products. May 2026 warning on products requiring but lacking approval, reported deaths and serious harms, absence of FDA quality and safety review, and reporting routes. Accessed .
- U.S. Food and Drug Administration. FDA approves first mesenchymal stromal cell therapy. Exact December 2024 approval, product, cell source, pediatric population, and steroid-refractory acute graft-versus-host disease indication for Ryoncil. Accessed .
- U.S. Food and Drug Administration. Regulatory considerations for human cells, tissues, and cellular and tissue-based products. FDA guidance on minimal manipulation, homologous use, and when an HCT/P is regulated as a drug, device, or biological product in addition to section 361 controls. Accessed .
- U.S. Food and Drug Administration. Regenerative Medicine Advanced Therapy designation. Statutory RMAT designation criteria and expedited-development benefits; the designation operates during development and is not marketing approval. Accessed .
- ClinicalTrials.gov. About ClinicalTrials.gov. Official statement that listing a study does not mean the U.S. government has reviewed or approved its safety or science. Accessed .
- Federal Trade Commission. Stem Cell Institute operators banned from marketing stem-cell treatments. January 2025 enforcement concerning deceptive efficacy and approval claims for marketed stem-cell treatments. Accessed .
- U.S. Food and Drug Administration. IND application procedures: overview. When an IND goes into effect, the 30-day safety-review period, clinical holds, and FDA notification that an investigation may proceed earlier. Accessed .
- U.S. Food and Drug Administration. Charging for investigational drugs under an IND: questions and answers. FDA's prior-written-authorization framework for an IND sponsor to charge for an investigational drug; it does not adjudicate every routine-care or service charge. Accessed .